Incyte | INCY - Despesas Operacionais

Preço das Ações
94.65
Mudança Diária
-0.82 -0.86%
Mensal
2.62%
Anual
59.99%
Q2 Previsão
92.62




Despesas Operacionais Alterar Data
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agenus USD 19.81M 293.94M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Novartis USD 9.8B 23M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12